Abstract
The human immunodeficiency virus (HIV) and the hepatitis B virus share common routes of transmission, and hence, coinfection with these two viruses is common. Chronic hepatitis B does not influence the progression of HIV disease or the response to highly active antiretroviral therapy. It is clear, however, that HIV infection does impact the course of hepatitis B, as higher rates of chronic carriage, lower seroconversion rates, and accelerated progression towards cirrhosis have been observed. Vaccination against hepatitis B is less effective in HIV-infected individuals. Coinfected subjects have a poor response to interferon therapy. Lamivudine is more effective in coinfected subjects but must not be used as monotherapy because of the risk of resistance developing. Combination therapy with lamivudine and tenofovir has shown promise and is currently being investigated in clinical trials, while new drugs and other combinations are in development.
Similar content being viewed by others
References
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, the HIV Outpatient Study Investigators (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853–860
Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J (1999) Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 15:1–4
Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J (2001) Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 17:1467–1471
Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S, Carosi G, the Hepatitis-HIV Study Group (2000) Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24:211–217
Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32:492–497
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921–1926
Unlinked Anonymous Surveys Steering Group (2001) Prevalence of HIV and hepatitis infections in the United Kingdom 2000. Department of Health, London. http://www.advisorybodies.doh.gov.uk/uassg/publications.htm
Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, Patroni A, Castelli F, Sacchi P, Filice G, Carosi G (2002) Hepatitis B virus coinfection in human immunodeficiency virus-infected subjects. AIDS Rev 4:27–35
Ahmed SD, Cuevas LE, Brabin BJ, Kazembe P, Broadhead R, Verhoeff FH, Hart CA (1998) Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 37:248–251
Lok ASF, McMahon BJ (2001) Chronic hepatitis B. Hepatology 34:1225–1241
Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2:479–486
Santos EA, Yoshida CFT, Rolla VC, Mendes JM, Vieira IF, Arabe J (2003) Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 22:9298
Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Okomadu C (2003) Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type 1-infected individuals. Clin Infect Dis 36:1602–1605
Gomez-Gonzalo M, Carretero M, Rullas J (2001) The hepatitis B virus × protein induces HIV-1 replication and transcription in synergy with T-cell activation signals. J Biol Chem 276:35435–35443
Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, Skaug K (1992) Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 6:571–574
Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM (1992) Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 117:837–838
Ockenga J, Tillmann C, Trautwein C, Stoll M, Manns MP, Schmidt RE (1997) Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J Hepatol 27:18–24
Solomon RE, VanRaden M, Kaslow RA, Lyter D, Visscher B, Farzadegan H, Phair J (1990) Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health 80:1475–1478
Palmon R, Shoultz DA, Levy DG, Dieterich DT (2002) Effect of hepatitis B on HIV infection. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract no. H-1738
Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, Gioannini P (1997) Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis 29:111–115
Gilson RJC, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IVD (1997) Interactions between HIV and hepatitis B virus in homosexual men: effects on natural history of infection. AIDS 11:597–606
Thio CL, Seaberg EC, Kingsley L, Phair J, Visscher B, Munoz A (2002) The role of hepatitis B virus in the progression of HIV and the response to highly active antiretroviral therapy (HAART). In: Program and abstracts of the XIV International AIDS Conference, Abstract no. B6016
Sheng WH, Hung CC, Chen MY, Hsieh SM, Wu CH, Hsiao CF (2003) Impact of chronic hepatitis B infection on outcomes of HIV-1 infected patients receiving HAART in an area hyperendemic for hepatitis B infection: an eight-year prospective observational study. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Abstract no. 823
Lincoln D, Petoumenos K, Dore GJ, on behalf of the Australian HIV Observational Database (2003) HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 4:241–249
De Luca A, Bugarini R, Cozzi Lepri A, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, d’Arminio Monforte A (2002) Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 162:2125–2132
Bodsworth NJ, Cooper DA, Donovan B (1991) The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163:1138–1140
Hadler SC, Judson FN, O’Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN, Francis DP (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163:454–459
Beck EJ, Mandalia S, Leonard K, Griffith RJ, Harris JRW, Miller DL (1996) Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission. Int J STD AIDS 7:34–38
Kellerman SE, Hanson DL, McNaghten AD, Fleming PL (2003) Prevalence of chronic hepatitis B and incidence of acute hepatitis B in human immunodeficiency virus-infected subjects. J Infect Dis 188:571–577
Bodsworth N, Donovan B, Nightingale BN (1989) The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 160:577–582
Koblin BA, Taylor PE, Rubinstein P, Stevens CE (1992) Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type 1 and hepatitis B viral replication. Hepatology 15:590–592
Krogsgaard K, Lindhart BO, Nielsen JO, Andersson P, Kryger P, Aldershvile J, Gerstoft J, Pederson C (1987) The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 7:37–41
Mai AL, Yim C, O’Rourke K, Heathcote EJ (1996) The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 22:299–304
Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, Berthelot P, Brechot C (1992) Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 15:578–583
Colin J-F, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Banhamou J, Erlinger S, Valla D, Marcelin P (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29:1306–1310
Trent Mills C, Lee E, Perrillo R (1990) Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 99:519–524
McDonald JA, Harris S, Waters JA, Thomas HC (1987) Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol 4:337–342
Perrillo R, Regenstein FG, Roodman ST (1986) Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 105:382–383
Bonacini M, Govindarajan S, Redeker AG (1991) Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 86:570–573
Rector WG, Govindarajan S, Horsburgh CR, Penley KA, Cohn DL, Judson FN (1988) Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol 83:262–266
Goldin RD, Fish DE, Hay A, Waters JA, McGarvey MJ, Main J, Thomas HC (1990) Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 43:203–205
Brau N, Leaf HL, Wieczorek RL, Margolis DM (1997) Severe hepatitis in three AIDS patients treated with indinavir. Lancet 349:924–925
Jeurissen FJF, Scneider MME, Borleffs JCC (1998) Is the combination of hepatitis and indinavir potentially dangerous? AIDS 12:441–442
Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:182–188
Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Riviere C, Chene G, Leport C (2000) Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 44:3451–3455
Bonfanti P, Landonia S, Ricci E, Martinelli C, Fortuna P, Faggion I, Quirino T (2001) Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27:316–318
den Brinker M, Wit FWNM, Wertheim-van Dillen PME, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling G, Lange JMA (2000) Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:2895–2902
Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM (2001) Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15:1261–1268
Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V (2001) Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27:426–431
Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 283:74–80
Aceti A, Pasquazzi C, Zechinki C, De Bac C (2002) Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 29:41–48
Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S (2001) Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 32:144–148
Carr A, Cooper DA (1997) Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349:995–996
Lemon SM, Thomas DL (1997) Vaccines to prevent viral hepatitis. N Engl J Med 336:196–204
Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O’Malley PM, Penley KA, Altman NL, Braff E, Shipman GF, Coleman PJ, Mandel EJ (1986) Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315:209–214
Carne CA, Weller IVD, Waite J, Briggs M, Pearce F, Adler MW, Tedder RS (1987) Impaired responsiveness of homosexual men with HIV antibodies to plasma-derived hepatitis B vaccine. Br Med J 294:866–868
Mannucci PM, Zanetti AR, Gringeri A, Tanzi E, Morfini M, Messori A, Tirindelli MC, De Biasi R, Ciavarella N, Colombo M (1989) Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 149:1333–1337
Collier AC, Corey L, Murphy VL, Handsfield HH (1988) Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 109:101–105
Odaka N, Eldred L, Cohn S, Munoz A, Fields HA, Fox R, Solomon R, Kaslow R, Polk F (1988) Comparative immunogenicity of plasma and recombinant hepatitis B vaccines in homosexual men. J Am Med Assoc 260:3635–3637
Tayal SC, Sankar KN (1994) Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 8:558–559
Rey D, Krantz V, Partisani M, Schmitt M-P, Meyer P, Libbrecht E, Wendling M, Vetter D, Nicolle M, Kempf-Durepaire G, Lang J (2000) Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18:1161–1165
European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561–565
Brook MG, Gilson R, Wilkins EL, on behalf of the British HIV Association (2003) BHIVA guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med 4(Suppl 1):42–51
Wong DKH, Cheung AM, O’Rourke K, Naylor D, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 119:312–323
McDonald JA, Caruso L, Karayiannis P, Scully LJ, Harris JRW, Forster GE, Thomas HC (1987) Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant α-interferon. Hepatology 7:719–723
Brook MG, McDonald JA, Karayiannis P, Caruso L, Forster G, Harris JRW, Thomas HC (1989) Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 30:1116–1122
Brook MG, Chan G, Yap I, Karayiannis P, Lever AML, Jacyna M, Main J, Thomas HC (1989) Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. Br Med J 299:652–656
Wong DKH, Yim C, Naylor CD, Chen E, Sherman M, Vas S, Wanless IR, Read S, Li H, Heathcote EJ (1995) Interferon alfa treatment of chronic hepatitis B: randomised trial in a predominantly homosexual male population. Gastroenterology 108:165–171
di Martino V, Thevenot T, Colin J-F, Boyer N, Martinot M, Degos F, Coulaud J, Vilde J, Vachon F, Degott C, Valla D, Marcellin P (2002) Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123:1812–1822
di Martino V, Thevenot T, Boyer N, Degos F, Valla D, Marcellin P (2000) Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology 31:1030–1031
Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao Y-C, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N (2003) Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis e antigen-positive chronic hepatitis B. J Viral Hepat 10:298–305
CAESAR Coordinating Committee (1997) Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 349:1413–1421
Lai C-L, Chien R-N, Leung N, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent J, Barber J, Stephenson SL, Gray DF (1998) A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61–68
Dore G, Cooper DA, Barrett C, Goh L-E, Thakrar B, Atkins M, for the CAESAR Coordinating Committee (1999) Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomised, controlled study (CAESAR). J Infect Dis 180:607–613
Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C et al (1995) Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345:396–397
Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolom P (1996) Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125:705–712
Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302–1306
Hoff J, Bani-Sadr F, Gassin M, Raffi F (2001) Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 32:963–969
Perrillo RP, Lai C-L, Liaw Y-F, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD (2002) Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36:186–194
Chien R-N, Liaw Y-F, Atkins M (1999) Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30:770–774
Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J (2003) Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 17:1649–1657
Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D, for the CAESAR Coordinating Committee (2000) Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS 14:1111–1116
Wolters LMM, Niesters HGM, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA (2002) Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 24:173–181
Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE (1999) Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28:1032–1035
Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Guttfreund K, Lamy P, Murray A (2000) Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129–133
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, Rizzelto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800–807
Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808–816
Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS (1998) Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669–1673
Gilson RJC, Chopra KB, Newell AM, Murray-Lyon IM, Nelson M, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IVD (1999) A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 6:387–395
Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T (2001) Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358:718–723
Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M, Brosgart C, Namini H, Poynard T, Katlama C (2002) Adefovir dipivoxil 10 mg suppresses HBV viral replication in HIV/HBV coinfected patients with lamivudine-resistant HBV. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Abstract no. 123
Delaugerre C, Marcelin A-G, Thibault V, Peytavin G, Bombled T, Bochet M-V, Katlama C, Benhamou Y, Calvez V (2002) Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 46:1586–1588
Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, Tebas P (2002) Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 186:1844–1847
Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Gaetano F (2003) Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus “e-minus” patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 17:783–784
Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B (2003) An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 17:F7–F10
Cooper D, Cheng A, Coakley D, Sayre J, Zhong L, Chen SS, Westland C, Miller M, Brosgart C (2002) Anti-HBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV coinfected. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Abstract no. 124
Marcelin AG, Tubiana R, Benhamou Y, Katlama C, Calvez V, Thibault V (2003) Long-term tenofovir treatment of lamivudine-resistant chronic hepatitis B in HIV co-infected patients. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Abstract no. 824
Benhamou Y, Tubiana R, Thibault V (2003) Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 348:177–178
van Bommel F, Wunsche T, Schurmann D, Berg T (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36:507–508
Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V (2002) Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 16:2352–2354
Gish RG, Leung NWY, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F (2002) Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 46:1734–1740
Raffi F, Snow A, Borrot-Esoda K, Shaw A, Anderson J, Sorbel J, Quinn J, Mondou E, Rousseau F (2003) Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Abstract no. 215
Lai CL, Rosmawati M, Lao J, van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D (2002) Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123:1831–1838
Chang T, Hadziyannis S, Cianciara J (2002) Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. In: Program and abstracts of the 53rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Abstract no. 550
Cooper D, Dore G, Pozniak AL, DeJesus E, Tran S, Sayre J, Lu B, Westland C, Miller MD, Coakley DF, Cheng A (2003) Tenofovir disoproxil fumarate and lamivudine combination therapy compared to lamivudine alone for HBV in therapy-naïve HIV/HBV co-infected patients: 48 week interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Abstract no. 825
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lessells, R., Leen, C. Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 23, 366–374 (2004). https://doi.org/10.1007/s10096-004-1127-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-004-1127-3